The scientific community is relentlessly working to investigate and fight SARS-CoV-2. Miltenyi Biotec stands committed to assisting those researchers in getting on top of COVID-19.
SARS-CoV-2 antigens offer researchers the possibility to investigate virus-specific immune responses, including antigen-specific B cells and antibodies.
All our antigens for SARS-CoV-2 research are available in different filling sizes and with or without biotinylation. Recombinantly expressed antigens are tagged with His and AviTag™. For more details, please vist the respective product pages linked in the table below.
Overview of our antigens for SARS-CoV-2 research
|SARS-CoV-2 lineage||Protein||Sequence part||Production system||Product page|
|n/a||ACE2||Full length (with CLD)||HEK cells||Recombinant Human ACE2 (HEK)|
|Truncated (w/o CLD)||Insect cells||Recombinant Human ACE2 (insect cells)|
|Wild-type variant||Spike protein||Spike trimer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Trimer (HEK)|
|Spike monomer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Prot (HEK)|
|Furin cleavage site (and control)||Chemical synthesis||SARS-CoV-2 Furin Cleavage Site|
SARS-CoV-2 Furin Cleavage Site Control
|Receptor binding domain (RBD)||HEK cells||Recombinant SARS-CoV-2 RBD (HEK)|
|Insect cells||Recombinant SARS-CoV-2 RBD (insect cells)|
|S1||HEK cells||Recombinant SARS-CoV-2 Spike-S1 (HEK)|
|S2||Insect cells||Recombinant SARS-CoV-2 Spike-S2 (insect cells)|
|Nucleoprotein||Full length||HEK cells||Recombinant SARS-CoV-2 Nucleoprotein|
|Envelope protein||C-terminus||Chemical synthesis||SARS-CoV-2 Envelope C-term|
|N-terminus||Chemical synthesis||SARS-CoV-2 Envelope N-term|
|Helical segment 2 (H2)||Chemical synthesis||SARS-CoV-2 Envelope H2|
|Mutated variants||B.1.1.7 (Alpha) |
|Spike monomer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Prot B.1.1.7 (HEK)|
|Receptor binding domain (RBD)||HEK cells||Recombinant SARS-CoV-2 RBD B.1.1.7 (HEK)|
|B.1.351 (Beta) |
|Spike monomer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Prot B.1.351 (HEK)|
|Receptor binding domain (RBD)||HEK cells||Recombinant SARS-CoV-2 RBD B.1.351 (HEK)|
|B.1.617.2 (Delta) spike protein ||Spike monomer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)|
|Receptor binding domain (RBD)||HEK cells||Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)|
|B.1.1.529/BA.1 (Omicron) spike protein||Spike monomer (ectodomain)||HEK cells||Recombinant SARS-CoV-2 Spike-Prot B.1.1.529/BA.1 (HEK)|
|Receptor binding domain (RBD)||HEK cells||Recombinant SARS-CoV-2 RBD B.1.1.529/BA.1 (HEK)|
Detection of patient-derived antibodies against SARS-CoV-2 antigens via a bead-based immunoassay
Biotinylated recombinant proteins coupled to streptavidin-coated PMMA beads can be applied to detect SARS-CoV-2–specific antibodies in plasmapheresis samples of COVID-19+ patients. The complete protocol can be found here.
Cell-based assay to analyze the binding of spike protein to native ACE2
The combination of recombinant spike RBD, monomer or trimer, and ACE2-expressing cells can be used to mimic the binding of SARS-CoV-2 to its host cells in vitro. Such binding assays can be applied to study inhibitory/neutralizing effects of components or antibodies.
If you have further questions or are interested in our proteins for SARS-CoV-2 research, please specify your question or request in the contact form and we will come back to you: